Rezulin troglitazone: Phase II; marketed to treat Type II diabetes

Dana-Farber Cancer Institute researchers and colleagues published in the Proceedings of the National Academy of Sciences the results of an open-label Phase II trial with troglitazone in 3 patients wit...